Brief: AC Immune’s Targeted Anti-pTau Active Immunotherapy For Alzheimer’s Disease Advances Into Phase 2B Trial

AC Immune AG

15/12/2023 12:36

Dec 15 (Reuters) - AC Immune SA  ACIU.O :
    * AC IMMUNE’S TARGETED ANTI-PTAU ACTIVE IMMUNOTHERAPY FOR
ALZHEIMER’S DISEASE ADVANCES INTO PHASE 2B TRIAL
    * AC IMMUNE SA - WILL NOW RECEIVE A MILESTONE PAYMENT OF CHF
15
MILLION
    * AC IMMUNE SA - WILL RECEIVE ANOTHER MILESTONE PAYMENT OF
CHF 25
MILLION RELATED TO ACHIEVING A NON-DISCLOSED ENROLLMENT TARGET

Source text for Eikon:  ID:nGNX7nqgx3 
Further company coverage:  ACIU.O 

 ((Reuters.Briefs@thomsonreuters.com;))